The “Big, Beautiful Bill” (H.R. 1) proposes $600–880 billion in Medicaid cuts over 10 years, threatening health coverage for nearly 11 million Americans. Yale and UPenn researchers estimate it would cause 51,000 unnecessary deaths each year, including 11,300 due to coverage loss.

Dexcom's new CGM replacement policy puts profits over patients' lives. While 37.3 million Americans with diabetes rely on continuous glucose monitors to prevent life-threatening complications, Dexcom now limits replacements for failed sensors to just three per year. When their adhesive fails - during everyday activities like exercising or showering - patients must choose between paying $400 monthly for replacements or risking their health by going without this essential monitoring device. Despite their $4 billion annual revenue, Dexcom is forcing patients to bear the cost of their product failures, highlighting the urgent need for FDA intervention.